Impax to pay $35 million to settle part of Solodyn antitrust litigation

by reuter.com
http://ift.tt/pnED7n
BOSTON (Reuters) - Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn.

Read more

Share on Facebook Share on Twitter Share on Google Plus

About New

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.